This study is comparing three different ways to treat obesity and related health problems: bariatric surgery (either RYGB or SG procedures), Semaglutide, or Tirzepatide. Researchers want to see how much weight you lose with each treatment. You might be able to join if you are between 18 and 70 years old, are eligible for bariatric surgery, and have a body mass index (BMI) between 35 and 65 kg/m2. This includes people with or without type 2 diabetes. The study is currently unclear on its recruitment status, but plans to enroll 125 participants.

Study design

This is a randomized study with 125 participants, comparing three groups: bariatric surgery, Semaglutide, or Tirzepatide. It is not blinded, meaning you and your doctors will know which treatment you are receiving.

What's involved

You will receive either bariatric surgery, Semaglutide, or Tirzepatide. Semaglutide and Tirzepatide involve weekly injections with a dose escalation period. The primary goal is to measure your weight loss over the first 52 weeks.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for a total of 24 months, with the first 12 months focusing on the main weight loss measurement and an additional 12 months as an extension phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.